NCT01701856View on ClinicalTrials.gov

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

PHASE4TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Interferon beta-1b

250 mcg, s.c., each other day for 12 months

Trial Locations (1)

6903

Ospedale Regionale di Lugano - Civico, Lugano

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Claudio Gobbi

OTHER_GOV